Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
6.55
-0.04 (-0.61%)
Aug 26, 2026, 12:12 PM EDT - Market open
Prelude Therapeutics Employees
Prelude Therapeutics had 79 employees as of December 31, 2025. The number of employees decreased by 52 or -39.69% compared to the previous year.
Employees
79
Change (1Y)
-52
Growth (1Y)
-39.69%
Revenue / Employee
$283,848
Profits / Employee
-$765,671
Market Cap
674.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 79 | -52 | -39.69% |
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Sep 30, 2022 | 120 | 7 | 6.19% |
| Jun 30, 2022 | 112 | 12 | 12.00% |
| Mar 31, 2022 | 118 | 13 | 12.38% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Sep 30, 2021 | 113 | 58 | 105.45% |
| Jun 30, 2021 | 100 | 49 | 96.08% |
| Mar 31, 2021 | 105 | 54 | 105.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Phathom Pharmaceuticals | 371 |
| CorMedix | 191 |
| MapLight Therapeutics | 133 |
| Verastem | 102 |
| OmniAb | 89 |
| AgomAb Therapeutics NV | 62 |
| Zevra Therapeutics | 61 |
PRLD News
- 15 days ago - Prelude Therapeutics Earnings release: Q2 2026 - Filings
- 15 days ago - Prelude Therapeutics Quarterly report: Q2 2026 - Filings
- 15 days ago - Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TheFly
- 16 days ago - Prelude Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline - TheFly
- 2 months ago - Prelude Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Prelude Therapeutics Transcript: AGM 2026 - Transcripts
- 3 months ago - Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts